Ad is loading...
AMGN
Price
$278.32
Change
+$0.22 (+0.08%)
Updated
Dec 3 closing price
62 days until earnings call
PFE
Price
$25.56
Change
-$0.26 (-1.01%)
Updated
Dec 3 closing price
62 days until earnings call
Ad is loading...

AMGN vs PFE

Header iconAMGN vs PFE Comparison
Open Charts AMGN vs PFEBanner chart's image
Amgen
Price$278.32
Change+$0.22 (+0.08%)
Volume$5.47M
CapitalizationN/A
Pfizer
Price$25.56
Change-$0.26 (-1.01%)
Volume$49.06M
CapitalizationN/A
AMGN vs PFE Comparison Chart
Loading...
AMGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
AMGN vs. PFE commentary
Dec 04, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a StrongSell and PFE is a StrongSell.

COMPARISON
Comparison
Dec 04, 2024
Stock price -- (AMGN: $278.32 vs. PFE: $25.56)
Brand notoriety: AMGN and PFE are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 178% vs. PFE: 114%
Market capitalization -- AMGN: $151.69B vs. PFE: $157.14B
AMGN [@Pharmaceuticals: Major] is valued at $151.69B. PFE’s [@Pharmaceuticals: Major] market capitalization is $157.14B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 4 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).

  • AMGN’s FA Score: 4 green, 1 red.
  • PFE’s FA Score: 1 green, 4 red.
According to our system of comparison, AMGN is a better buy in the long-term than PFE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 4 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).

  • AMGN’s TA Score: 4 bullish, 5 bearish.
  • PFE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, PFE is a better buy in the short-term than AMGN.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а -0.60% price change this week, while PFE (@Pharmaceuticals: Major) price change was -0.81% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.61%. For the same industry, the average monthly price growth was -6.00%, and the average quarterly price growth was +1.19%.

Reported Earning Dates

AMGN is expected to report earnings on Feb 04, 2025.

PFE is expected to report earnings on Feb 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.61% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PFE($157B) and AMGN($152B) have the same market capitalization . PFE has higher P/E ratio than AMGN: PFE (74.92) vs AMGN (22.66). AMGN YTD gains are higher at: -0.448 vs. PFE (-5.792). AMGN has higher annual earnings (EBITDA): 14.8B vs. PFE (9.56B). PFE has more cash in the bank: 12.7B vs. AMGN (10.9B). AMGN has less debt than PFE: AMGN (64.6B) vs PFE (70.8B). PFE has higher revenues than AMGN: PFE (58.5B) vs AMGN (28.2B).
AMGNPFEAMGN / PFE
Capitalization152B157B97%
EBITDA14.8B9.56B155%
Gain YTD-0.448-5.7928%
P/E Ratio22.6674.9230%
Revenue28.2B58.5B48%
Total Cash10.9B12.7B86%
Total Debt64.6B70.8B91%
FUNDAMENTALS RATINGS
AMGN vs PFE: Fundamental Ratings
AMGN
PFE
OUTLOOK RATING
1..100
65
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
4
Undervalued
PROFIT vs RISK RATING
1..100
25100
SMR RATING
1..100
1883
PRICE GROWTH RATING
1..100
6362
P/E GROWTH RATING
1..100
1696
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (4) in the Pharmaceuticals Major industry is in the same range as AMGN (18) in the Biotechnology industry. This means that PFE’s stock grew similarly to AMGN’s over the last 12 months.

AMGN's Profit vs Risk Rating (25) in the Biotechnology industry is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.

AMGN's SMR Rating (18) in the Biotechnology industry is somewhat better than the same rating for PFE (83) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than PFE’s over the last 12 months.

PFE's Price Growth Rating (62) in the Pharmaceuticals Major industry is in the same range as AMGN (63) in the Biotechnology industry. This means that PFE’s stock grew similarly to AMGN’s over the last 12 months.

AMGN's P/E Growth Rating (16) in the Biotechnology industry is significantly better than the same rating for PFE (96) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNPFE
RSI
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
65%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
55%
Bearish Trend 1 day ago
67%
Momentum
ODDS (%)
Bearish Trend 1 day ago
51%
Bullish Trend 1 day ago
52%
MACD
ODDS (%)
Bearish Trend 1 day ago
38%
Bullish Trend 1 day ago
54%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
57%
Bearish Trend 1 day ago
66%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
49%
Bearish Trend 1 day ago
61%
Advances
ODDS (%)
Bullish Trend 6 days ago
54%
Bullish Trend 6 days ago
57%
Declines
ODDS (%)
Bearish Trend 9 days ago
52%
Bearish Trend 1 day ago
63%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
48%
Aroon
ODDS (%)
Bearish Trend 1 day ago
50%
Bearish Trend 1 day ago
60%
View a ticker or compare two or three
Ad is loading...
AMGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
USAU7.980.04
+0.50%
US Gold Corp
THG163.280.76
+0.47%
Hanover Insurance Group (The)
PRU127.15-1.26
-0.98%
Prudential Financial
CRSR7.84-0.15
-1.88%
Corsair Gaming
VNDA4.91-0.13
-2.58%
Vanda Pharmaceuticals